
Former GSK Oncology president joins Kesios
pharmafile | June 1, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, Paolo Paoletti, kesios
The Imperial Innovations Group has confirmed the appointment of Dr Paolo Paoletti to be the executive chairman of Kesios Therapeutics.
Paoletti was formerly the first appointed president of GSK Oncology, where as the leader of its business unit he was responsible for the overall oncology portfolio within GlaxoSmithKline – from early drug discovery through clinical development, launch and life cycle management.
Paoletti is also non-executive director of PsiOxus Therapeutics, Innovation’s sixth largest portfolio company, which is developing innovative oncolytic immuno-oncology treatments for cancer.
UK-based Kesios, which is in the Imperial incubator in South Kensington, was created to develop and commercialise certain research from the Department of Medicine at Imperial College London.
Paoletti says: “I’m extremely pleased to take this role to accelerate the clinical development of this new molecule and, hopefully, to translate the very innovative and interesting pre-clinical science in an impactful medicine for patients affected by Multiple Myeloma and other forms of cancer.”
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …






